Display Settings:

Format

Send to:

Choose Destination
Accession: PRJNA472053 ID: 472053

Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant II (human)

See Genome Information for Homo sapiens
Gene expression profiling was performed on OCI-AML2 R50 drug resistant leukemia cell line before or after Romidepsin treatment. Overall design: mRNA profiles of OCI-AML2 R50 cells with or without Romidepsin treatment
AccessionPRJNA472053; GEO: GSE114648
Data TypeTranscriptome or Gene expression
ScopeMultiisolate
OrganismHomo sapiens[Taxonomy ID: 9606]
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo; Homo sapiens
Publications
  • Yan B et al., "Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia.", Leukemia, 2020 Jul;34(7):1816-1827
  • Yan B et al., "Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.", Leukemia, 2019 Apr;33(4):931-944
SubmissionRegistration date: 18-May-2018
University of Florida
RelevanceMedical
Project Data:
Resource NameNumber
of Links
Sequence data
SRA Experiments3
Publications
PubMed2
PMC1
Other datasets
BioSample3
GEO DataSets1
GEO Data Details
ParameterValue
Data volume, Supplementary Mbytes1
SRA Data Details
ParameterValue
Data volume, Gbases36
Data volume, Mbytes15278

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center